IgG4相关性疾病诊治中国专家共识2021

引用：张文,董凌莉,朱剑,等. IgG 4相关性疾病诊治中国专家共识 [J]. 中华内科杂志,2021,60(3):192-206.

DOI:10.3760/cma.j.cn112138-20200803-00726.

【Summary】

IgG 4 related disease (IgG 4 ‐RD) is an immune medicated rare disease,characterized with chronic inflammation and fibrosis in the involved organs, it is a systemic disease diverse clinical manifestations. Due to the the relative novelty of the disease and under‐recognition,the overall level of diagnosis and treatment in China is uneven. Till now, there is no relevant expert consensus or guidance of IgG 4 ‐RD in China. In order to further improve the understanding and standardize the management of IgG 4 ‐RD, on the basis of summarizing domestic and international experience, the China Alliance For Rare Diseases, together with the Chinese Rheumatology  Association, organized an expert group and established the Chinese expert consensus on the diagnosis and treatment of IgG 4 related diseases.

摘要： 

IgG 4相关性疾病（IgG 4-RD）是一种较罕见的由免疫介导的慢性炎症伴纤维化疾病，可累及全身多个器官和系统，临床表现复杂多样。由于对该病认识时间较短，我国IgG 4-RD的整体诊治水平参差不齐，国内亦无相关专家共识或诊治指南。为进一步提高各专业医生对IgG 4-RD的认识和规范诊治水平，由中国罕见病联盟与中华医学会风湿病学分会联合组织专家组，在总结国内外经验和研究结果的基础上，制定了本共识，旨在统一我国临床医生对该病的诊治认识，减少漏诊和误诊，改善患者预后。

免责声明：本号旨在帮助医疗卫生专业人士更好地了解相关医学知识。所发布的内容，并不代表同意其描述和观点，仅仅为了分享更多知识。所发布的内容不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。所发布的内容，著作权均归作者本人所有，若有侵权，或版权个人或单位不想在本号发布，可联系微信gabstudy，本号将立即将其撤除。